Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.

In 73 extensive-stage SCLC patients treated with anlotinib, no demographic/clinical characteristic was related to tumor cavitation, and tumor cavitation was an independent factor in predicting better PFS.